A major discovery of inflammatory bowel disease (IBD) research in the past decade has been the elucidation of bacteria as necessary for disease pathogenesis. However, no particularly bacterial species, or antigen have been identified. In ulcerative colitis (UC) marker antibodies against neutrophil components (pANCA) have been identified in 68-85 percent of patients. With only 6 percent of the other idiopathic IBD, Crohn's disease (CD) scoring positive for pANCA, this represents specific diagnostic tool. Using a monoclonal anti-neutrophil antibody (5-3 antibody), they have identified two novel antigens implicated in IBD pathogenesis. Both the E. coli OmpC protein and the Mycobacterium Tb, HupB proteins are recognized by 5-3 antibody. The goal of this project is to develop and optimize ELISAs based on these proteins. Satisfaction of Phase I of this proposal will establish novel diagnostics for this disease, and represent the first stage of evaluation of these targets for design of a therapeutic regimen.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK058451-01
Application #
6210744
Study Section
Special Emphasis Panel (ZRG1-SSS-4 (01))
Program Officer
Podskalny, Judith M
Project Start
2000-09-30
Project End
2001-09-29
Budget Start
2000-09-30
Budget End
2001-09-29
Support Year
1
Fiscal Year
2000
Total Cost
$99,850
Indirect Cost
Name
Prometheus Laboratories, Inc.
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121